154 related articles for article (PubMed ID: 29258672)
21. Vogt-Koyanagi-Harada Syndrome Induced by Pembrolizumab in a Patient with Non-Small Cell Lung Cancer.
Tamura T; Akimoto E; Matsumoto C; Mori S; Nishi T; Kudo K; Kuyama S
J Thorac Oncol; 2018 Oct; 13(10):1606-1607. PubMed ID: 29730378
[No Abstract] [Full Text] [Related]
22. Histologic Transformation in a Patient with Lung Cancer Treated with Chemotherapy and Pembrolizumab.
Hsu CL; Chen KY; Kuo SW; Chang YL
J Thorac Oncol; 2017 Jun; 12(6):e75-e76. PubMed ID: 28532567
[No Abstract] [Full Text] [Related]
23. Psoriatic arthritis induced by anti-programmed death 1 antibody pembrolizumab.
Hara T; Mikita N; Ikeda T; Inaba Y; Kunimoto K; Kaminaka C; Kanazawa N; Yamamoto Y; Jinnin M
J Dermatol; 2019 Dec; 46(12):e466-e467. PubMed ID: 31376178
[No Abstract] [Full Text] [Related]
24. Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma.
Vallet H; Gaillet A; Weiss N; Vanhaecke C; Saheb S; Touitou V; Franck N; Kramkimel N; Borden A; Touat M; Ricard D; Verny M; Maisonobe T; Psimaras D
Ann Oncol; 2016 Jul; 27(7):1352-3. PubMed ID: 26940685
[No Abstract] [Full Text] [Related]
25. Pembrolizumab induced severe sclerodermoid reaction.
Shenoy N; Esplin B; Barbosa N; Wieland C; Thanarajasingam U; Markovic S
Ann Oncol; 2017 Feb; 28(2):432-433. PubMed ID: 27742656
[No Abstract] [Full Text] [Related]
26. Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm.
Haddox CL; Shenoy N; Shah KK; Kao JC; Jain S; Halfdanarson TR; Wijdicks EF; Goetz MP
Ann Oncol; 2017 Mar; 28(3):673-675. PubMed ID: 27993808
[No Abstract] [Full Text] [Related]
27. Rupioid psoriasis induced by pembrolizumab.
Marti-Marti I; Gómez S; Riera-Monroig J; Carrera C; Mascaró JM
Indian J Dermatol Venereol Leprol; 2020; 86(5):580-582. PubMed ID: 32719194
[No Abstract] [Full Text] [Related]
28. Pembrolizumab-induced myasthenia gravis: A fatal case report.
March KL; Samarin MJ; Sodhi A; Owens RE
J Oncol Pharm Pract; 2018 Mar; 24(2):146-149. PubMed ID: 28147928
[TBL] [Abstract][Full Text] [Related]
29. In brief: Pembrolizumab (Keytruda) for cancers with biomarkers.
Med Lett Drugs Ther; 2018 Jan; 60(1537):e8. PubMed ID: 29294466
[No Abstract] [Full Text] [Related]
30. Pembrolizumab-Related Sarcoid-Like Reaction Presenting as Reactivation of Quiescent Scars.
McKenna MC; Molloy K; Crowther S; Feeney J; Gillis A; Connolly M; Kelleher F
J Oncol Pract; 2018 Mar; 14(3):200-201. PubMed ID: 29300520
[No Abstract] [Full Text] [Related]
31. [Pembrolizumab for the treatment of melanoma: updates and perspectives.].
Chiarion Sileni V; Mandalà M; Queirolo P
Recenti Prog Med; 2017 Dec; 108(12):528-531. PubMed ID: 29297903
[TBL] [Abstract][Full Text] [Related]
32. Severe polyradiculoneuritis associated with the combination of ipilimumab and pembrolizumab in a lung cancer patient.
Cho HS; Lee KY; Hu CJ; Chung CC
Neurol India; 2018; 66(2):509-511. PubMed ID: 29547174
[No Abstract] [Full Text] [Related]
33. Generalized morphea in the setting of pembrolizumab.
Cheng MW; Hisaw LD; Bernet L
Int J Dermatol; 2019 Jun; 58(6):736-738. PubMed ID: 29931792
[No Abstract] [Full Text] [Related]
34. Severe bullous pemphigoid in a metastatic lung cancer patient treated with pembrolizumab.
Adachi E; Honda T; Nonoyama S; Irie H; Yamamura K; Otsuka A; Kabashima K
J Dermatol; 2019 Jul; 46(7):e232-e233. PubMed ID: 30758879
[No Abstract] [Full Text] [Related]
35. Pembrolizumab-induced hepatitis: diagnosis and treatment.
Forschner A; Schraml C; Pierchalla K; Weide B; Eigentler TK; Lauer UM; Garbe C
J Dtsch Dermatol Ges; 2017 Sep; 15(9):933-935. PubMed ID: 28872228
[No Abstract] [Full Text] [Related]
36. Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab.
Nasr F; El Rassy E; Maalouf G; Azar C; Haddad F; Helou J; Robert C
Eur J Cancer; 2018 Mar; 91():171-173. PubMed ID: 29287903
[No Abstract] [Full Text] [Related]
37. Hypothyroid ataxia complicating monoclonal antibody therapy.
Badran A; Moran C; Coles AJ
Pract Neurol; 2017 Dec; 17(6):482-484. PubMed ID: 28778931
[TBL] [Abstract][Full Text] [Related]
38. Hemophagocytic lymphohistiocytosis secondary to pembrolizumab treatment with insufficient response to high-dose steroids.
Lorenz G; Schul L; Bachmann Q; Angermann S; Slotta-Huspenina J; Heemann U; Küchle C; Schmaderer C; Jäger M; Tauber R; Retz M; Moog P
Rheumatology (Oxford); 2019 Jun; 58(6):1106-1109. PubMed ID: 30668880
[No Abstract] [Full Text] [Related]
39. Pembrolizumab for classical Hodgkin's lymphoma.
Burki TK
Lancet Oncol; 2016 Aug; 17(8):e324. PubMed ID: 27397043
[No Abstract] [Full Text] [Related]
40. Pembrolizumab in advanced head and neck cancer.
Brower V
Lancet Oncol; 2017 May; 18(5):e248. PubMed ID: 28366274
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
